Pathogenesis of the antiphospholipid syndrome

Seminars in Thrombosis and Hemostasis

Volumn 38, Issue 4, 2012, Pages 305-321

  Willis, Rohan ^a,b   Harris, E Nigel ^b   Pierangeli, Silvia S ^a  

^a University of Texas Medical Branch School of Medicine   (United States)

^b UNIVERSITY OF THE WEST INDIES   (Jamaica)

Author keywords

anti glycoprotein I antibodies; anticardiolipin antibodies; antiphospholipid antibodies; antiphospholipid syndrome; lupus anticoagulant

Indexed keywords

ACETYLSALICYLIC ACID; ACTIVATED PROTEIN C; ANTIPLASMIN; APOLIPOPROTEIN E2; BETA2 GLYCOPROTEIN 1 ANTIBODY; CARDIOLIPIN ANTIBODY; COMPLEMENT COMPONENT C5 INHIBITOR; COMPLEMENT MEMBRANE ATTACK COMPLEX; COVERSIN; CYTOSOLIC PHOSPHOLIPASE A2; FLUINDOSTATIN; HEPARIN; IMMUNOGLOBULIN A2; IMMUNOGLOBULIN F(AB')2 FRAGMENT; IMMUNOGLOBULIN G4; LIPOCORTIN 2; MITOGEN ACTIVATED PROTEIN KINASE 14; MITOGEN ACTIVATED PROTEIN KINASE KINASE 1; MYELOID DIFFERENTIATION FACTOR 88; PHOSPHOLIPID ANTIBODY; RITUXIMAB; ROSUVASTATIN; TOLL LIKE RECEPTOR 7; TOLL LIKE RECEPTOR 9; TOLL LIKE RECEPTOR AGONIST; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; UNINDEXED DRUG; VASCULOTROPIN; VASCULOTROPIN RECEPTOR 1; WARFARIN;

ACTIVE IMMUNIZATION; AMINO ACID SYNTHESIS; ANGIOGENESIS; ANTIBODY PRODUCTION; ANTIBODY TITER; ANTIGEN BINDING; ANTIPHOSPHOLIPID SYNDROME; APOPTOSIS; BLOOD CLOTTING; CELL ACTIVATION; CELL MEMBRANE; COMPLEMENT ACTIVATION; COMPLEMENT CLASSICAL PATHWAY; COMPLEMENT DEPOSITION; CYTOKINE PRODUCTION; DNA BINDING; DRUG EFFECT; ENDOTHELIUM CELL; ENVIRONMENTAL FACTOR; FETUS WASTAGE; FIBRINOLYSIS; GENE EXPRESSION; HEREDITY; HUMAN; HYPOCOMPLEMENTEMIA; IMMUNE SYSTEM; IMMUNOGLOBULIN PRODUCTION; IN VITRO STUDY; IN VIVO STUDY; INFLAMMATION; INFLAMMATORY INFILTRATE; INTRAUTERINE GROWTH RETARDATION; LOW DRUG DOSE; MICROCIRCULATION; MORBIDITY; NONHUMAN; OXIDATION; OXIDATIVE STRESS; PATHOPHYSIOLOGY; PLACENTA CIRCULATION; PREGNANCY; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN DOMAIN; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; REVIEW; SIGNAL TRANSDUCTION; SKIN ULCER; TH1 CELL; THROMBOCYTE ACTIVATION; THROMBOCYTOPENIA; THROMBOGENESIS; THROMBOSIS; TREATMENT DURATION; UPREGULATION;

ANIMALS; ANTIPHOSPHOLIPID SYNDROME; DISEASE MODELS, ANIMAL; FEMALE; HUMANS; PREGNANCY; PREGNANCY COMPLICATIONS;

EID: 84861345859     PISSN: 00946176     EISSN: 10989064     Source Type: Journal    
DOI: 10.1055/s-0032-1311827     Document Type: Review

References (181)

1. Harris EN. Syndrome of the black swan. Br J Rheumatol: 1987; 26 5 324 326
2. Wilson WA, Gharavi AE, Koike T., et al. International consensus statement on preliminary classification criteria for definite antiphospholipid syndrome: report of an international workshop. Arthritis Rheum: 1999; 42 7 1309 1311 (Pubitemid 30265586)
3. Miyakis S, Lockshin MD, Atsumi T., et al. International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). J Thromb Haemost: 2006; 4 2 295 306
4. McNeil HP, Simpson RJ, Chesterman CN, Krilis SA. Anti-phospholipid antibodies are directed against a complex antigen that includes a lipid-binding inhibitor of coagulation: 2-glycoprotein I (apolipoprotein H). Proc Natl Acad Sci U S A: 1990; 87 11 4120 4124
5. Galli M, Comfurius P, Maassen C., et al. Anticardiolipin antibodies (ACA) directed not to cardiolipin but to a plasma protein cofactor. Lancet: 1990; 335 8705 1544 1547 (Pubitemid 20189625)
6. Amengual O, Atsumi T, Koike T. Antiprothombin antibodies and the diagnosis of antiphospholipid syndrome. Clin Immunol: 2004; 112 2 144 149 (Pubitemid 38881479)
7. Permpikul P, Rao LV, Rapaport SI. Functional and binding studies of the roles of prothrombin and beta 2-glycoprotein I in the expression of lupus anticoagulant activity. Blood: 1994; 83 10 2878 2892
8. Boey ML, Colaco CB, Gharavi AE, Elkon KB, Loizou S, Hughes GRV. Thrombosis in SLE: striking association with the presence of circulating lupus anticoagulant. Br Med J (Clin Res Ed): 1983; 287 1021 1023 (Pubitemid 13009248)
9. Ginsburg KS, Liang MH, Newcomer L., et al. Anticardiolipin antibodies and the risk for ischemic stroke and venous thrombosis. Ann Intern Med: 1992; 117 12 997 1002
10. McClain MT, Arbuckle MR, Heinlen LD., et al. The prevalence, onset, and clinical significance of antiphospholipid antibodies prior to diagnosis of systemic lupus erythematosus. Arthritis Rheum: 2004; 50 4 1226 1232 (Pubitemid 38480833)
11. Tincani A, Balestrieri G, Danieli E., et al. Pregnancy complications of the antiphospholipid syndrome. Autoimmunity: 2003; 36 1 27 32 (Pubitemid 36321905)
12. Levine JS, Branch DW, Rauch J. The antiphospholipid syndrome. N Engl J Med: 2002; 346 10 752 763 (Pubitemid 34983997)
13. Sailer T, Zaglami C, Kurz C., et al. Anti-beta(2)-glycoprotein-I antibodies are associated with pregnancy loss in women with the lupus anticoagulant. Thromb Haemost: 2006; 95 796 801
14. Petri M. Update on anti-phospholipid antibodies in SLE: the Hopkins' Lupus Cohort. Lupus: 2010; 19 4 419 423
15. Chen PP, Giles I. Antibodies to serine proteases in the antiphospholipid syndrome. Curr Rheumatol Rep: 2010; 12 1 45 52
16. Meroni PL, Raschi E, Camera M., et al. Endothelial activation by aPL: a potential pathogenetic mechanism for the clinical manifestations of the syndrome. J Autoimmun: 2000; 15 2 237 240
17. Urbanus RT, Derksen RH, de Groot PG. Platelets and the antiphospholipid syndrome. Lupus: 2008; 17 10 888 894
18. Nojima J, Suehisa E, Kuratsune H., et al. Platelet activation induced by combined effects of anticardiolipin and lupus anticoagulant IgG antibodies in patients with systemic lupus erythematosuspossible association with thrombotic and thrombocytopenic complications. Thromb Haemost: 1999; 81 3 436 441 (Pubitemid 29116617)
19. Krone KA, Allen KL, McCrae KR. Impaired fibrinolysis in the antiphospholipid syndrome. Curr Rheumatol Rep: 2010; 12 1 53 57
20. Ames PR, Antinolfi I, Ciampa A., et al. Primary antiphospholipid syndrome: a low-grade auto-inflammatory disease? Rheumatology (Oxford): 2008; 47 12 1832 1837
21. Abrahams VM. Mechanisms of antiphospholipid antibody-associated pregnancy complications. Thromb Res: 2009; 124 5 521 525
22. Erkan D, Lockshin MD. Non-criteria manifestations of antiphospholipid syndrome. Lupus: 2010; 19 4 424 427
23. D'Ippolito S, Di Simone N, Di Nicuolo F, Castellani R, Caruso A. Antiphospholipid antibodies: effects on trophoblast and endothelial cells. Am J Reprod Immunol: 2007; 58 2 150 158 (Pubitemid 47097381)
24. Di Simone N, Luigi MP, Marco D., et al. Pregnancies complicated with antiphospholipid syndrome: the pathogenic mechanism of antiphospholipid antibodies: a review of the literature. Ann N Y Acad Sci: 2007; 1108 505 514 (Pubitemid 47528765)
25. Katsiari CG, Giavri I, Mitsikostas DD, Yiannopoulou KG, Sfikakis PP. Acute transverse myelitis and antiphospholipid antibodies in lupus. No evidence for anticoagulation. Eur J Neurol: 2011; 18 4 556 563
26. Gharavi AE, Pierangeli SS, Harris EN. Origin of antiphospholipid antibodies. Rheum Dis Clin North Am: 2001; 27 3 551 563 (Pubitemid 32781414)
27. Rauch J, Dieud M, Subang R, Levine JS. The dual role of innate immunity in the antiphospholipid syndrome. Lupus: 2010; 19 4 347 353
28. Lambrianides A, Carroll CJ, Pierangeli SS., et al. Effects of polyclonal IgG derived from patients with different clinical types of the antiphospholipid syndrome on monocyte signaling pathways. J Immunol: 2010; 184 12 6622 6628
29. Jiang H, Chess L. How the immune system achieves self-nonself discrimination during adaptive immunity. Adv Immunol: 2009; 102 95 133
30. Hashimoto Y, Kawamura M, Ichikawa K., et al. Anticardiolipin antibodies in NZW x BXSB F1 mice. A model of antiphospholipid syndrome. J Immunol: 1992; 149 3 1063 1068
31. Hang LM, Izui S, Dixon FJ. (NZW x BXSB)F1 hybrid. A model of acute lupus and coronary vascular disease with myocardial infarction. J Exp Med: 1981; 154 1 216 221 (Pubitemid 11079819)
32. Oyaizu N, Yasumizu R, Miyama-Inaba M., et al. (NZW x BXSB)F1 mouse. A new animal model of idiopathic thrombocytopenic purpura. J Exp Med: 1988; 167 6 2017 2022
33. Kita Y, Sumida T, Iwamoto I, Yoshida S, Koike T. V gene analysis of anti-cardiolipin antibodies from (NZW x BXSB) F1 mice. Immunology: 1994; 82 3 494 501 (Pubitemid 24251636)
34. Gharavi AE, Sammaritano LR, Wen J, Elkon KB. Induction of antiphospholipid autoantibodies by immunization with beta 2 glycoprotein I (apolipoprotein H). J Clin Invest: 1992; 90 3 1105 1109
35. Gharavi AE, Pierangeli SS, Colden-Stanfield M, Liu XW, Espinola RG, Harris EN. GDKV-induced antiphospholipid antibodies enhance thrombosis and activate endothelial cells in vivo and in vitro. J Immunol: 1999; 163 5 2922 2927 (Pubitemid 29399224)
36. Gharavi AE, Pierangeli SS, Gharavi EE., et al. Thrombogenic properties of antiphospholipid antibodies do not depend on their binding to beta2 glycoprotein 1 (beta2GP1) alone. Lupus: 1998; 7 5 341 346 (Pubitemid 28347014)
37. Gharavi EE, Chaimovich H, Cucurull E., et al. Induction of antiphospholipid antibodies by immunization with synthetic viral and bacterial peptides. Lupus: 1999; 8 6 449 455 (Pubitemid 29423579)
38. Gharavi AE, Pierangeli SS, Espinola RG, Liu X, Colden-Stanfield M, Harris EN. Antiphospholipid antibodies induced in mice by immunization with a cytomegalovirus-derived peptide cause thrombosis and activation of endothelial cells in vivo. Arthritis Rheum: 2002; 46 2 545 552 (Pubitemid 34136593)
39. Gharavi AE, Vega-Ostertag M, Espinola RG., et al. Intrauterine fetal death in mice caused by cytomegalovirus-derived peptide induced aPL antibodies. Lupus: 2004; 13 1 17 23 (Pubitemid 38129346)
40. Blank M, Krause I, Fridkin M., et al. Bacterial induction of autoantibodies to beta2-glycoprotein-I accounts for the infectious etiology of antiphospholipid syndrome. J Clin Invest: 2002; 109 6 797 804 (Pubitemid 34263156)
41. Uthman IW, Gharavi AE. Viral infections and antiphospholipid antibodies. Semin Arthritis Rheum: 2002; 31 4 256 263 (Pubitemid 34160809)
42. Sne D, Piette JC, Cacoub P. [Antiphospholipid antibodies, antiphospholipid syndrome and viral infections]. Rev Med Interne: 2009; 30 2 135 141
43. Van O S GM, Meijers JC, Agar C., et al. Induction of anti-2 -glycoprotein I autoantibodies in mice by protein H of Streptococcus pyogenes. J Thromb Haemost: 2011; 9 12 2447 2456
44. Passam FH, Giannakopoulos B, Mirarabshahi P, Krilis SA. Molecular pathophysiology of the antiphospholipid syndrome: the role of oxidative post-translational modification of beta 2 glycoprotein I. J Thromb Haemost: 2011; 9 1 275 282
45. Aguilar-Valenzuela R, Nickerson K, Romay-Penabad Z., et al. Involvement of TLR7 and TLR9 in the production of antiphospholipid antibodies. Arthritis Rheum: 2011; 63 10 s281 (abstract 723)
46. Papalardo E, Romay-Penabad Z, Christadoss P, Pierangeli S. Induction of pathogenic antiphospholipid antibodies in vivo are dependent on expression of MHC-II genes. Lupus: 2010; 19 496 (abstract)
47. Dagenais P, Urowitz MB, Gladman DD, Norman CS. A family study of the antiphospholipid syndrome associated with other autoimmune diseases. J Rheumatol: 1992; 19 9 1393 1396
48. Asherson RA, Doherty DG, Vergani D, Khamashta MA, Hughes GR. Major histocompatibility complex associations with primary antiphospholipid syndrome. Arthritis Rheum: 1992; 35 1 124 125
49. Caliz R, Atsumi T, Kondeatis E., et al. HLA class II gene polymorphisms in antiphospholipid syndrome: haplotype analysis in 83 Caucasoid patients. Rheumatology (Oxford): 2001; 40 1 31 36
50. Galeazzi M, Sebastiani GD, Tincani A., et al. HLA class II alleles associations of anticardiolipin and anti-beta2GPI antibodies in a large series of European patients with systemic lupus erythematosus. Lupus: 2000; 9 1 47 55 (Pubitemid 30265118)
51. Wilson WA, Perez MC, Michalski JP, Armatis PE. Cardiolipin antibodies and null alleles of C4 in black Americans with systemic lupus erythematosus. J Rheumatol: 1988; 15 12 1768 1772 (Pubitemid 19037643)
52. Hirose N, Williams R, Alberts AR., et al. A role for the polymorphism at position 247 of the beta2-glycoprotein I gene in the generation of anti-beta2-glycoprotein I antibodies in the antiphospholipid syndrome. Arthritis Rheum: 1999; 42 8 1655 1661 (Pubitemid 30263634)
53. Pierangeli SS, Barker JH, Stikovac D., et al. Effect of human IgG antiphospholipid antibodies on an in vivo thrombosis model in mice. Thromb Haemost: 1994; 71 5 670 674
54. Stockmans F, Deckmyn H, Gruwez J, Vermylen J, Acland R. Continuous quantitative monitoring of mural, platelet-dependent, thrombus kinetics in the crushed rat femoral vein. Thromb Haemost: 1991; 65 4 425 431
55. Barker JH, Gu JM, Anderson GL., et al. The effects of heparin and dietary fish oil on embolic events and the microcirculation downstream from a small-artery repair. Plast Reconstr Surg: 1993; 91 2 335 343 (Pubitemid 23088597)
56. Pierangeli SS, Liu XW, Barker JH, Anderson G, Harris EN. Induction of thrombosis in a mouse model by IgG, IgM and IgA immunoglobulins from patients with the antiphospholipid syndrome. Thromb Haemost: 1995; 74 5 1361 1367
57. Olee T, Pierangeli SS, Handley HH., et al. Generation and characterization of monoclonal IgG anticardiolipin antibodies from a patient with the antiphospholipid syndrome. Proc Natl Acad Sci U S A: 1996; 93 8606 8611 (Pubitemid 26269607)
58. Pierangeli SS, Liu SW, Anderson G, Barker JH, Harris EN. Thrombogenic properties of murine anti-cardiolipin antibodies induced by 2 glycoprotein 1 and human immunoglobulin G antiphospholipid antibodies. Circulation: 1996; 94 7 1746 1751 (Pubitemid 26320284)
59. Jankowski M, Vreys I, Wittevrongel C., et al. Thrombogenicity of beta 2-glycoprotein I-dependent antiphospholipid antibodies in a photochemically induced thrombosis model in the hamster. Blood: 2003; 101 1 157 162 (Pubitemid 36025902)
60. Fischetti F, Durigutto P, Pellis V., et al. Thrombus formation induced by antibodies to beta2-glycoprotein I is complement dependent and requires a priming factor. Blood: 2005; 106 7 2340 2346 (Pubitemid 41510805)
61. 2- glycoprotein-1 autoantibodies from patients with antiphospholipid syndrome are sufficient to potentiate arterial thrombus formation in a mouse model. Blood: 2011; 117 12 3453 3459
62. Pierangeli SS, Colden-Stanfield M, Liu X, Barker JH, Anderson GL, Harris EN. Antiphospholipid antibodies from antiphospholipid syndrome patients activate endothelial cells in vitro and in vivo. Circulation: 1999; 99 15 1997 2002 (Pubitemid 29183897)
63. Pierangeli SS, Espinola RG, Liu X, Harris EN. Thrombogenic effects of antiphospholipid antibodies are mediated by intercellular cell adhesion molecule-1, vascular cell adhesion molecule-1, and P-selectin. Circ Res: 2001; 88 2 245 250 (Pubitemid 32147315)
64. Pierangeli SS, Liu X, Espinola R., et al. Functional analyses of patient-derived IgG monoclonal anticardiolipin antibodies using in vivo thrombosis and in vivo microcirculation models. Thromb Haemost: 2000; 84 3 388 395
65. Aron AL, Cuellar ML, Brey RL., et al. Early onset of autoimmunity in MRL/++ mice following immunization with beta 2 glycoprotein I. Clin Exp Immunol: 1995; 101 1 78 81
66. Branch DW, Dudley DJ, Mitchell MD., et al. Immunoglobulin G fractions from patients with antiphospholipid antibodies cause fetal death in BALB/c mice: a model for autoimmune fetal loss. Am J Obstet Gynecol: 1990; 163 1 Pt 1 210 216 (Pubitemid 20253090)
67. Bakimer R, Fishman P, Blank M, Sredni B, Djaldetti M, Shoenfeld Y. Induction of primary antiphospholipid syndrome in mice by immunization with a human monoclonal anticardiolipin antibody (H-3). J Clin Invest: 1992; 89 5 1558 1563
68. Fishman P, Falach-Vaknine E, Zigelman R., et al. Prevention of fetal loss in experimental antiphospholipid syndrome by in vivo administration of recombinant interleukin-3. J Clin Invest: 1993; 91 4 1834 1837 (Pubitemid 23127392)
69. Holers VM, Girardi G, Mo L., et al. Complement C3 activation is required for antiphospholipid antibody-induced fetal loss. J Exp Med: 2002; 195 2 211 220 (Pubitemid 34461265)
70. Girardi G, Berman J, Redecha P., et al. Complement C5a receptors and neutrophils mediate fetal injury in the antiphospholipid syndrome. J Clin Invest: 2003; 112 11 1644 1654 (Pubitemid 38063722)
71. Girardi G, Redecha P, Salmon JE. Heparin prevents antiphospholipid antibody-induced fetal loss by inhibiting complement activation. Nat Med: 2004; 10 11 1222 1226 (Pubitemid 39540439)
72. Simantov R, Lo SK, Gharavi A, Sammaritano LR, Salmon JE, Silverstein RL. Antiphospholipid antibodies activate vascular endothelial cells. Lupus: 1996; 5 5 440 441 (Pubitemid 26354062)
73. Kornberg A, Blank M, Kaufman S, Shoenfeld Y. Induction of tissue factor-like activity in monocytes by anti-cardiolipin antibodies. J Immunol: 1994; 153 3 1328 1332 (Pubitemid 24228525)
74. Reverter JC, Tssies D, Font J., et al. Effects of human monoclonal anticardiolipin antibodies on platelet function and on tissue factor expression on monocytes. Arthritis Rheum: 1998; 41 8 1420 1427 (Pubitemid 28373121)
75. Forastiero R, Martinuzzo M, Carreras LO, Maclouf J. Anti-beta2 glycoprotein I antibodies and platelet activation in patients with antiphospholipid antibodies: association with increased excretion of platelet-derived thromboxane urinary metabolites. Thromb Haemost: 1998; 79 1 42 45 (Pubitemid 28037054)
76. Lellouche F, Martinuzzo M, Said P, Maclouf J, Carreras LO. Imbalance of thromboxane/prostacyclin biosynthesis in patients with lupus anticoagulant. Blood: 1991; 78 11 2894 2899
77. Khamashta MA, Harris EN, Gharavi AE., et al. Immune mediated mechanism for thrombosis: antiphospholipid antibody binding to platelet membranes. Ann Rheum Dis: 1988; 47 10 849 854
78. Lutters BC, Derksen RH, Tekelenburg WL, Lenting PJ, Arnout J, de Groot PG. Dimers of beta 2-glycoprotein I increase platelet deposition to collagen via interaction with phospholipids and the apolipoprotein E receptor 2 J Biol Chem: 2003; 278 36 33831 33838 (Pubitemid 37553217)
79. Espinola RG, Pierangeli SS, Gharavi AE, Harris EN. Hydroxychloroquine reverses platelet activation induced by human IgG antiphospholipid antibodies. Thromb Haemost: 2002; 87 3 518 522 (Pubitemid 34232495)
80. Pierangeli SS, Vega-Ostertag M, Harris EN. Intracellular signaling triggered by antiphospholipid antibodies in platelets and endothelial cells: a pathway to targeted therapies. Thromb Res: 2004; 114 5-6 467 476 (Pubitemid 39429425)
81. Shi T, Giannakopoulos B, Yan X., et al. Anti-beta2-glycoprotein I antibodies in complex with beta2-glycoprotein I can activate platelets in a dysregulated manner via glycoprotein Ib-IX-V. Arthritis Rheum: 2006; 54 8 2558 2567 (Pubitemid 44205017)
82. Urbanus RT, Pennings MT, Derksen RH, de Groot PG. Platelet activation by dimeric beta2-glycoprotein I requires signaling via both glycoprotein Ibalpha and apolipoprotein E receptor 2 J Thromb Haemost: 2008; 6 8 1405 1412 (Pubitemid 352016322)
83. Sikara MP, Routsias JG, Samiotaki M, Panayotou G, Moutsopoulos HM, Vlachoyiannopoulos PG. beta2 Glycoprotein I (beta2GPI) binds platelet factor 4 (PF4): implications for the pathogenesis of antiphospholipid syndrome. Blood: 2010; 115 3 713 723
84. Amengual O, Atsumi T, Khamashta MA, Hughes GR. The role of the tissue factor pathway in the hypercoagulable state in patients with the antiphospholipid syndrome. Thromb Haemost: 1998; 79 2 276 281 (Pubitemid 28065869)
85. Alijotas-Reig J, Palacio-Garcia C, Vilardell-Tarres M. Circulating microparticles, lupus anticoagulant and recurrent miscarriages. Eur J Obstet Gynecol Reprod Biol: 2009; 145 1 22 26
86. Cuadrado MJ, Buenda P, Velasco F., et al. Vascular endothelial growth factor expression in monocytes from patients with primary antiphospholipid syndrome. J Thromb Haemost: 2006; 4 11 2461 2469 (Pubitemid 44575442)
87. Lopez-Pedrera C, Perez-Sandrez C, Ruiz-Limon P., et al. Mitochondrial dysfunction in monocytes from antiphospholipid sundrome patients: implications in the pathogenesis of the disease and effects of coenzyme treatment. Arthritis Rheum: 2011; 63 10 s282 (abstract 725)
88. Vega-Ostertag ME, Ferrara DE, Romay-Penabad Z., et al. Role of p38 mitogen-activated protein kinase in antiphospholipid antibody-mediated thrombosis and endothelial cell activation. J Thromb Haemost: 2007; 5 9 1828 1834 (Pubitemid 47288938)
89. Lpez-Pedrera C, Buenda P, Cuadrado MJ., et al. Antiphospholipid antibodies from patients with the antiphospholipid syndrome induce monocyte tissue factor expression through the simultaneous activation of NF-kappaB/Rel proteins via the p38 mitogen-activated protein kinase pathway, and of the MEK-1/ERK pathway. Arthritis Rheum: 2006; 54 1 301 311 (Pubitemid 43122214)
90. Romay-Penabad Z, Carrera-Marin AL, Mackman N, Pierangeli S. Pathogenic effects of antiphospholipid antibodies are ameliorated in tissue factor deficient mice. Arthritis Rheum: 2011; 63 10 s5 (abstract 13)
91. Romay-Penabad Z, Montiel-Manzano MG, Shilagard T., et al. Annexin A2 is involved in antiphospholipid antibody-mediated pathogenic effects in vitro and in vivo. Blood: 2009; 114 14 3074 3083
92. Zhang J, McCrae KR. Annexin A2 mediates endothelial cell activation by antiphospholipid/anti-beta2 glycoprotein I antibodies. Blood: 2005; 105 5 1964 1969 (Pubitemid 40731779)
93. Raschi E, Testoni C, Bosisio D., et al. Role of the MyD88 transduction signaling pathway in endothelial activation by antiphospholipid antibodies. Blood: 2003; 101 9 3495 3500 (Pubitemid 36857933)
94. Pierangeli SS, Vega-Ostertag ME, Raschi E., et al. Toll-like receptor and antiphospholipid mediated thrombosis: in vivo studies. Ann Rheum Dis: 2007; 66 10 1327 1333 (Pubitemid 47492476)
95. Sorice M, Longo A, Capozzi A., et al. Anti-beta2-glycoprotein I antibodies induce monocyte release of tumor necrosis factor alpha and tissue factor by signal transduction pathways involving lipid rafts. Arthritis Rheum: 2007; 56 8 2687 2697 (Pubitemid 47237287)
96. Allen KL, Fonseca FV, Betapudi V, Willard B, Zhang J, McCrae KR. A novel pathway for human endothelial cell activation by antiphospholipid/anti-2 glycoprotein I antibodies. Blood: 2012; 119 884 893
97. Döring Y, Hurst J, Lorenz M., et al. Human antiphospholipid antibodies induce TNFalpha in monocytes via toll-like receptor 8. Immunobiology: 2010; 215 3 230 241
98. Hurst J, Prinz N, Lorenz M., et al. TLR7 and TLR8 ligands and antiphospholipid antibodies show synergistic effects on the induction of IL-1beta and caspase-1 in monocytes and dendritic cells. Immunobiology: 2009; 214 8 683 691
99. Prinz N, Clemens N, Strand D., et al. Antiphospholipid antibodies induce translocation of TLR7 and TLR8 to the endosome in human monocytes and plasmacytoid dendritic cells. Blood: 2011; 118 8 2322 2332
100. Barton GM, Kagan JC, Medzhitov R. Intracellular localization of Toll-like receptor 9 prevents recognition of self DNA but facilitates access to viral DNA. Nat Immunol: 2006; 7 1 49 56 (Pubitemid 41823868)
101. Raschi E, Broggini V, Grossi C, Borghi MO, Pierangeli SS, Meroni PL. Mechanisms of action of antiphospholipid antibodies. In: Cervera R, Asherson R, Khamashta M, Reverter JC. eds. Handbook of Systemic Autoimmune Diseases. Antiphospholipid Syndrome in Systemic Autoimmune Disease. Oxford, UK Elsevier: 2009; 10 55 67
102. Romay-Penabad Z, Aguilar-Valenzuela R, Urbanus RT., et al. Apolipoprotein E receptor 2 is involved in the thrombotic complications in a murine model of the antiphospholipid syndrome. Blood: 2011; 117 4 1408 1414
103. Zhao Y, Rumold R, Zhu M., et al. An IgG antiprothrombin antibody enhances prothrombin binding to damaged endothelial cells and shortens plasma coagulation times. Arthritis Rheum: 1999; 42 10 2132 2138 (Pubitemid 30263596)
104. Vega-Ostertag M, Liu X, Kwan-Ki H, Chen P, Pierangeli S. A human monoclonal antiprothrombin antibody is thrombogenic in vivo and upregulates expression of tissue factor and E-selectin on endothelial cells. Br J Haematol: 2006; 135 2 214 219 (Pubitemid 44401619)
105. Atsumi T, Ieko M, Bertolaccini ML., et al. Association of autoantibodies against the phosphatidylserine-prothrombin complex with manifestations of the antiphospholipid syndrome and with the presence of lupus anticoagulant. Arthritis Rheum: 2000; 43 9 1982 1993
106. Hwang KK, Grossman JM, Visvanathan S., et al. Identification of anti-thrombin antibodies in the antiphospholipid syndrome that interfere with the inactivation of thrombin by antithrombin. J Immunol: 2001; 167 12 7192 7198 (Pubitemid 33144217)
107. Escolar G, Font J, Reverter JC., et al. Plasma from systemic lupus erythematosus patients with antiphospholipid antibodies promotes platelet aggregation. Studies in a perfusion system. Arterioscler Thromb: 1992; 12 2 196 200
108. Yang YH, Chien D, Wu M., et al. Novel autoantibodies against the activated coagulation factor IX (FIXa) in the antiphospholipid syndrome that interpose the FIXa regulation by antithrombin. J Immunol: 2009; 182 3 1674 1680
109. Yang YH, Hwang KK, FitzGerald J., et al. Antibodies against the activated coagulation factor X (FXa) in the antiphospholipid syndrome that interfere with the FXa inactivation by antithrombin. J Immunol: 2006; 177 11 8219 8225
110. Griffin JH, Fernndez JA, Gale AJ, Mosnier LO. Activated protein C. J Thromb Haemost: 2007; 5 1 73 80 (Pubitemid 46958820)
111. Marciniak E, Romond EH. Impaired catalytic function of activated protein C: a new in vitro manifestation of lupus anticoagulant. Blood: 1989; 74 7 2426 2432 (Pubitemid 19286462)
112. Hwang KK, Yang CD, Yan W, Grossman JM, Hahn BH, Chen PP. A thrombin-cross-reactive anticardiolipin antibody binds to and inhibits the anticoagulant function of activated protein C. Arthritis Rheum: 2003; 48 6 1622 1630 (Pubitemid 36682370)
113. Chamley LW, McKay EJ, Pattison NS. Inhibition of heparin/antithrombin III cofactor activity by anticardiolipin antibodies: a mechanism for thrombosis. Thromb Res: 1993; 71 2 103 111 (Pubitemid 23190635)
114. Yang CD, Hwang KK, Yan W., et al. Identification of anti-plasmin antibodies in the antiphospholipid syndrome that inhibit degradation of fibrin. J Immunol: 2004; 172 9 5765 5773 (Pubitemid 38542082)
115. Kolev K, Gombs J, Vradi B., et al. Immunoglobulin G from patients with antiphospholipid syndrome impairs the fibrin dissolution with plasmin. Thromb Haemost: 2002; 87 3 502 508 (Pubitemid 34232493)
116. Lu CS, Horizon AA, Hwang KK., et al. Identification of polyclonal and monoclonal antibodies against tissue plasminogen activator in the antiphospholipid syndrome. Arthritis Rheum: 2005; 52 12 4018 4027 (Pubitemid 41798242)
117. Cugno M, Cabibbe M, Galli M., et al. Antibodies to tissue-type plasminogen activator (tPA) in patients with antiphospholipid syndrome: evidence of interaction between the antibodies and the catalytic domain of tPA in 2 patients. Blood: 2004; 103 6 2121 2126 (Pubitemid 38326228)
118. Ames PR, Tommasino C, Iannaccone L, Brillante M, Cimino R, Brancaccio V. Coagulation activation and fibrinolytic imbalance in subjects with idiopathic antiphospholipid antibodiesa crucial role for acquired free protein S deficiency. Thromb Haemost: 1996; 76 2 190 194 (Pubitemid 26285249)
119. Cesarman GM, Guevara CA, Hajjar KA. An endothelial cell receptor for plasminogen/tissue plasminogen activator (t-PA). II. Annexin II-mediated enhancement of t-PA-dependent plasminogen activation. J Biol Chem: 1994; 269 33 21198 21203
120. Ao W, Zheng H, Chen XW, Shen Y, Yang CD. Anti-annexin II antibody is associated with thrombosis and/or pregnancy morbidity in antiphospholipid syndrome and systemic lupus erythematosus with thrombosis. Rheumatol Int: 2011; 31 7 865 869
121. Cesarman-Maus G, Ros-Luna NP, Deora AB., et al. Autoantibodies against the fibrinolytic receptor, annexin 2, in antiphospholipid syndrome. Blood: 2006; 107 11 4375 4382 (Pubitemid 43801363)
122. Pierangeli SS, Girardi G, Vega-Ostertag M, Liu X, Espinola RG, Salmon J. Requirement of activation of complement C3 and C5 for antiphospholipid antibody-mediated thrombophilia. Arthritis Rheum: 2005; 52 7 2120 2124 (Pubitemid 40994335)
123. Romay-Penabad Z, Liu XX, Montiel-Manzano G, Papalardo De Martnez E, Pierangeli SS. C5a receptor-deficient mice are protected from thrombophilia and endothelial cell activation induced by some antiphospholipid antibodies. Ann N Y Acad Sci: 2007; 1108 554 566 (Pubitemid 47528769)
124. Carrera-Marin AL, Romay-Penabad Z, Qu HC., et al. A C5a Receptor Antagonist Ameliorates In Vivo Effects of Antiphospholipid Antibodies. Arthritis Rheum: 2009; 60 s767 (abstract)
125. Carrera-Marin AL, Aguilar-Valenzuela R, Romay-Penabad Z., et al. Involvement of C6 and the MAC on in vivo antiphospholipid-mediated pathogenic effects. Lupus: 2010; 19 507 (abstract)
126. Carrera-Marin AL, Romay-Penabad Z, Machin S, Cohen H, Pierangeli S. C5 inhibitor rEV576 ameliorates in vivo effects of antiphospholipid antibodies. Arthritis Rheum: 2011; 63 10 s5 (abstract 12)
127. Oku K, Atsumi T, Bohgaki M., et al. Complement activation in patients with primary antiphospholipid syndrome. Ann Rheum Dis: 2009; 68 6 1030 1035
128. De Wolf F, Carreras LO, Moerman P, Vermylen J, Van Assche A, Renaer M. Decidual vasculopathy and extensive placental infarction in a patient with repeated thromboembolic accidents, recurrent fetal loss, and a lupus anticoagulant. Am J Obstet Gynecol: 1982; 142 7 829 834 (Pubitemid 12142941)
129. Peaceman AM, Rehnberg KA. The effect of immunoglobulin G fractions from patients with lupus anticoagulant on placental prostacyclin and thromboxane production. Am J Obstet Gynecol: 1993; 169 6 1403 1406 (Pubitemid 24009168)
130. Hanly JG, Gladman DD, Rose TH, Laskin CA, Urowitz MB. Lupus pregnancy. A prospective study of placental changes. Arthritis Rheum: 1988; 31 3 358 366 (Pubitemid 18091658)
131. Nayar R, Lage JM. Placental changes in a first trimester missed abortion in maternal systemic lupus erythematosus with antiphospholipid syndrome; a case report and review of the literature. Hum Pathol: 1996; 27 2 201 206 (Pubitemid 26049477)
132. Krikun G, Lockwood CJ, Wu XX., et al. The expression of the placental anticoagulant protein, annexin V, by villous trophoblasts: immunolocalization and in vitro regulation. Placenta: 1994; 15 6 601 612 (Pubitemid 24295067)
133. Rand JH, Wu XX, Guller S., et al. Reduction of annexin-V (placental anticoagulant protein-I) on placental villi of women with antiphospholipid antibodies and recurrent spontaneous abortion. Am J Obstet Gynecol: 1994; 171 6 1566 1572
134. Rand JH, Wu XX, Guller S, Scher J, Andree HA, Lockwood CJ. Antiphospholipid immunoglobulin G antibodies reduce annexin-V levels on syncytiotrophoblast apical membranes and in culture media of placental villi. Am J Obstet Gynecol: 1997; 177 4 918 923 (Pubitemid 27516067)
135. Wang X, Campos B, Kaetzel MA, Dedman JR. Annexin V is critical in the maintenance of murine placental integrity. Am J Obstet Gynecol: 1999; 180 4 1008 1016 (Pubitemid 29200569)
136. Nojima J, Kuratsune H, Suehisa E., et al. Association between the prevalence of antibodies to beta(2)-glycoprotein I, prothrombin, protein C, protein S, and annexin V in patients with systemic lupus erythematosus and thrombotic and thrombocytopenic complications. Clin Chem: 2001; 47 6 1008 1015 (Pubitemid 32493585)
137. Donohoe S, Kingdom JC, Mackie IJ., et al. Ontogeny of beta 2 glycoprotein I and annexin V in villous placenta of normal and antiphospholipid syndrome pregnancies. Thromb Haemost: 2000; 84 1 32 38 (Pubitemid 30433664)
138. Out HJ, Kooijman CD, Bruinse HW, Derksen RH. Histopathological findings in placentae from patients with intra-uterine fetal death and anti-phospholipid antibodies. Eur J Obstet Gynecol Reprod Biol: 1991; 41 3 179 186
139. McIntyre JA. Immune recognition at the maternal-fetal interface: overview. Am J Reprod Immunol: 1992; 28 3-4 127 131 (Pubitemid 23044812)
140. Castellucci M, De Matteis R, Meisser A., et al. Leptin modulates extracellular matrix molecules and metalloproteinases: possible implications for trophoblast invasion. Mol Hum Reprod: 2000; 6 10 951 958
141. Di Simone N, Meroni PL, de Papa N., et al. Antiphospholipid antibodies affect trophoblast gonadotropin secretion and invasiveness by binding directly and through adhered beta2-glycoprotein I. Arthritis Rheum: 2000; 43 1 140 150 (Pubitemid 30368223)
142. Katsuragawa H, Kanzaki H, Inoue T, Hirano T, Mori T, Rote NS. Monoclonal antibody against phosphatidylserine inhibits in vitro human trophoblastic
143. Adler RR, Ng AK, Rote NS. Monoclonal antiphosphatidylserine antibody inhibits intercellular fusion of the choriocarcinoma line, JAR. Biol Reprod: 1995; 53 4 905 910
144. Chamley LW, Duncalf AM, Mitchell MD, Johnson PM. Action of anticardiolipin and antibodies to beta2-glycoprotein-I on trophoblast proliferation as a mechanism for fetal death. Lancet: 1998; 352 9133 1037 1038 (Pubitemid 28438584)
145. Rote NS, Vogt E, DeVere G, Obringer AR, Ng AK. The role of placental trophoblast in the pathophysiology of the antiphospholipid antibody syndrome. Am J Reprod Immunol: 1998; 39 2 125 136 (Pubitemid 28062284)
146. Di Simone N, Castellani R, Caliandro D, Caruso A. Antiphospholid antibodies regulate the expression of trophoblast cell adhesion molecules. Fertil Steril: 2002; 77 4 805 811 (Pubitemid 34275366)
147. Di Simone N, Marana R, Castellani R., et al. Decreased expression of heparin-binding epidermal growth factor-like growth factor as a newly identified pathogenic mechanism of antiphospholipid-mediated defective placentation. Arthritis Rheum: 2010; 62 5 1504 1512
148. Ornoy A, Yacobi S, Matalon ST., et al. The effects of antiphospholipid antibodies obtained from women with SLE/APS and associated pregnancy loss on rat embryos and placental explants in culture. Lupus: 2003; 12 7 573 578 (Pubitemid 36890154)
149. Matalon ST, Shoenfeld Y, Blank M, Yacobi S, von Landenberg P, Ornoy A. Antiphosphatidylserine antibodies affect rat yolk sacs in culture: a mechanism for fetal loss in antiphospholipid syndrome. Am J Reprod Immunol: 2004; 51 2 144 151 (Pubitemid 38239741)
150. di Simone N, Castellani R, Raschi E, Borghi MO, Meroni PL, Caruso A. Anti-beta-2 glycoprotein I antibodies affect Bcl-2 and Bax trophoblast expression without evidence of apoptosis. Ann N Y Acad Sci: 2006; 1069 364 376 (Pubitemid 43989879)
151. 2glycoprotein I antibodies. Clin Exp Rheumatol: 2007; 2 35
152. Francis J, Rai R, Sebire NJ., et al. Impaired expression of endometrial differentiation markers and complement regulatory proteins in patients with recurrent pregnancy loss associated with antiphospholipid syndrome. Mol Hum Reprod: 2006; 12 7 435 442 (Pubitemid 44288202)
153. Di Simone N, Di Nicuolo F, D'Ippolito S., et al. Antiphospholipid antibodies affect human endometrial angiogenesis. Biol Reprod: 2010; 83 2 212 219
154. Riley JK, Nelson DM. Toll-like receptors in pregnancy disorders and placental dysfunction. Clin Rev Allergy Immunol: 2010; 39 185 193
155. Bogic LV, Ohira RH, Yamamoto SY, Okazaki KJ, Millar K, Bryant-Greenwood GD. Tissue plasminogen activator and its receptor in the human amnion, chorion, and decidua at preterm and term. Biol Reprod: 1999; 60 4 1006 1012 (Pubitemid 29149389)
156. Mulla MJ, Brosens JJ, Chamley LW., et al. Antiphospholipid antibodies induce a pro-inflammatory response in first trimester trophoblast via the TLR4/MyD88 pathway. Am J Reprod Immunol: 2009; 62 2 96 111
157. Mulla MJ, Myrtolli K, Brosens JJ., et al. Antiphospholipid antibodies limit trophoblast migration by reducing IL-6 production and STAT3 activity. Am J Reprod Immunol: 2010; 63 5 339 348
158. Chaouat G. The Th1/Th2 paradigm: still important in pregnancy? Semin Immunopathol: 2007; 29 2 95 113 (Pubitemid 47603024)
159. Martinez de la Torre Y, Buracchi C, Borroni EM., et al. Protection against inflammation- and autoantibody-caused fetal loss by the chemokine decoy receptor D6. Proc Natl Acad Sci U S A: 2007; 104 7 2319 2324 (Pubitemid 46391395)
160. Quigg RJ, Kozono Y, Berthiaume D., et al. Blockade of antibody-induced glomerulonephritis with Crry-Ig, a soluble murine complement inhibitor. J Immunol: 1998; 160 9 4553 4560 (Pubitemid 28217315)
161. Redecha P, Tilley R, Tencati M., et al. Tissue factor: a link between C5a and neutrophil activation in antiphospholipid antibody induced fetal injury. Blood: 2007; 110 7 2423 2431 (Pubitemid 47523163)
162. Girardi G, Yarilin D, Thurman JM, Holers VM, Salmon JE. Complement activation induces dysregulation of angiogenic factors and causes fetal rejection and growth restriction. J Exp Med: 2006; 203 9 2165 2175 (Pubitemid 44352237)
163. Shamonki JM, Salmon JE, Hyjek E, Baergen RN. Excessive complement activation is associated with placental injury in patients with antiphospholipid antibodies. Am J Obstet Gynecol: 2007; 196 2 167.e1 167.e5
164. Cavazzana I, Manuela N, Irene C., et al. Complement activation in anti-phospholipid syndrome: a clue for an inflammatory process? J Autoimmun: 2007; 28 2-3 160 164 (Pubitemid 46680500)
165. Stone S, Pijnenborg R, Vercruysse L., et al. The placental bed in pregnancies complicated by primary antiphospholipid syndrome. Placenta: 2006; 27 4-5 457 467
166. Buyon JP, Garabet L, Kim M., et al. Favorable prognosis in a large, prospective multicenter study of lupus pregnancies. Arthritis Rheum: 2011; 63 10 s669 (abstract 1707)
167. Ruiz-Irastorza G, Cuadrado MJ, Ruiz-Arruza I., et al. Evidence-based recommendations for the prevention and long-term management of thrombosis in antiphospholipid antibody-positive patients: report of a task force at the 13th International Congress on antiphospholipid antibodies. Lupus: 2011; 20 2 206 218
168. Edwards MH, Pierangeli SS, Liu X, Barker JH, Anderson G, Harris EN. Hydroxychloroquine reverses thrombogenic properties of antiphospholipid antibodies in mice. Circulation: 1997; 96 12 4380 4384 (Pubitemid 28007469)
169. Kaiser R, Cleveland CM, Criswell LA. Risk and protective factors for thrombosis in systemic lupus erythematosus: results from a large, multi-ethnic cohort. Ann Rheum Dis: 2009; 68 2 238 241
170. Ferrara DE, Liu X, Espinola RG., et al. Inhibition of the thrombogenic and inflammatory properties of antiphospholipid antibodies by fluvastatin in an in vivo animal model. Arthritis Rheum: 2003; 48 11 3272 3279 (Pubitemid 37409342)
171. Murthy V, Erkan D, Jajoria P., et al. Effects of fluvastatin on pro-inflammatory and pro-thrombotic markers in antiphospholipid antibody (aPL)-positive patients: preliminary results from an open-label prospective pilot study. Arthritis Rheum: 2011; 63 10 s283 (abstract 726)
172. Erre GL, Pardini S, Faedda R, Passiu G. Effect of rituximab on clinical and laboratory features of antiphospholipid syndrome: a case report and a review of literature. Lupus: 2008; 17 1 50 55 (Pubitemid 351487020)
173. Erkan D, Vega J, Ramon G, Kozora E, Lockshin MD. Rituximab in antiphospholipid syndrome (RITAPS)a pilot open-label phase II prospective trial for non-criteria manifestations of antiphospholipid antibodies (aPL). Arthritis Rheum: 2011; 63 10 s283 (abstract 727)
174. Zhou H, Wolberg AS, Roubey RA. Characterization of monocyte tissue factor activity induced by IgG antiphospholipid antibodies and inhibition by dilazep. Blood: 2004; 104 8 2353 2358 (Pubitemid 39331833)
175. Simoncini S, Sapet C, Camoin-Jau L., et al. Role of reactive oxygen species and p38 MAPK in the induction of the pro-adhesive endothelial state mediated by IgG from patients with anti-phospholipid syndrome. Int Immunol: 2005; 17 4 489 500 (Pubitemid 40568124)
176. Ostertag MV, Liu X, Henderson V, Pierangeli SS. A peptide that mimics the Vth region of beta-2-glycoprotein I reverses antiphospholipid-mediated thrombosis in mice. Lupus: 2006; 15 6 358 365 (Pubitemid 44032711)
177. Martinez de la Torre Y, Pregnolato F, D'Amelio F, Grossi C, Disimone N., et al. Anti-phospholipid induced murine fetal loss: novel protective effect of a peptide targeting the 2 glycoprotein I phospholipid-binding site. Implications for human fetal loss. J Autoimmun: 2011; 38 J209 J215
178. Sebire NJ, Fox H, Backos M, Rai R, Paterson C, Regan L. Defective endovascular trophoblast invasion in primary antiphospholipid antibody syndrome-associated early pregnancy failure. Hum Reprod: 2002; 17 4 1067 1071 (Pubitemid 34411147)
179. Shamshirsaz AA, Paidas M, Krikun G. Preeclampsia, hypoxia, thrombosis, and inflammation. J Pregnancy: 2012; 2012 374047
180. Lambrianides A, Carroll C, Pericleous C., et al. Differential clinical manifestations of the antiphospholipid syndrome may be predicted by different intracellular signaling pathways. Arthritis Rheum: 2007; 56 S9 S533
181. Carroll TY, Mulla MJ, Han CS., et al. Modulation of trophoblast angiogenic factor secretion by antiphospholipid antibodies is not reversed by heparin. Am J Reprod Immunol: 2011; 66 4 286 296